p-cresyl sulfate and indoxyl sulfate in pediatric patients on chronic dialysis

Korean Journal of Pediatrics

Volumn 56, Issue 4, 2013, Pages 159-164

  Hyun, Hye Sun ^a   Paik, Kyung Hoon ^a   Cho, Hee Yeon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Children; Chronic dialysis; Indoxyl sulfate; p cresyl sulfate; Probiotics

Indexed keywords

INDICAN; PROBIOTIC AGENT; UREMIC TOXIN; VSL3;

ADOLESCENT; ADULT; ARTICLE; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; CATABOLISM; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSIS; FEMALE; HEMATURIA; HEMODIALYSIS; HUMAN; INFANT; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS BULGARICUS; LACTOBACILLUS CASEI; LACTOBACILLUS PLANTARUM; LIQUID CHROMATOGRAPHY; MALE; PERITONEAL DIALYSIS; PRESCHOOL CHILD; PROSPECTIVE STUDY; QUESTIONNAIRE; SCHOOL CHILD; STREPTOCOCCUS THERMOPHILUS;

EID: 84876465398     PISSN: 17381061     EISSN: 20927258     Source Type: Journal    
DOI: 10.3345/kjp.2013.56.4.159     Document Type: Article

References (21)

1. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-1943.
2. Vanholder R, De Smet R. Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 1999;10:1815-23.
3. Fagugli RM, De Smet R, Buoncristiani U, Lameire N, Vanholder R. Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis 2002;40:339-47.
4. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Vanholder R, Brunet P. Protein-bound toxins: update 2009. Semin Dial 2009; 22:334-9.
5. Meyer TW, Hostetter TH. Uremia. N Engl J Med 2007;357:1316-25.
6. Meijers BK, De Loor H, Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P. p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:1932-8.
7. Evenepoel P, Meijers BK, Bammens BR, Verbeke K. Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl 2009;(114):S12-9.
8. Lin CJ, Wu CJ, Pan CF, Chen YC, Sun FJ, Chen HH. Serum proteinbound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant 2010;25:3693-700.
9. Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lac tic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996;74:349-55.
10. Nakabayashi I, Nakamura M, Kawakami K, Ohta T, Kato I, Uchida K, et al. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrol Dial Transplant 2011;26:1094-8.
11. de Loor H, Meijers BK, Meyer TW, Bammens B, Verbeke K, Dehaen W, et al. Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography. J Chromatogr A 2009;1216:4684-8.
12. Pham NM, Recht NS, Hostetter TH, Meyer TW. Removal of the protein-bound solutes indican and p-cresol sulfate by peritoneal dialysis. Clin J Am Soc Nephrol 2008;3:85-90.
13. Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y. Superior dialytic clearance of beta(2)-microglobulin and p-cresol by highflux hemodialysis as compared to peritoneal dialysis. Kidney Int 2006;70:794-9.
14. Meijers BK, Bammens B, Verbeke K, Evenepoel P. A review of albumin binding in CKD. Am J Kidney Dis 2008;51:839-50.
15. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of the protein-bound solute p-cresol by convective transport: a randomized crossover study. Am J Kidney Dis 2004;44:278-85.
16. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Time profiles of peritoneal and renal clearances of different uremic solutes in incident peritoneal dialysis patients. Am J Kidney Dis 2005;4 6:512-9.
17. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 2003;64: 2238-43.
18. Liabeuf S, Drueke TB, Massy ZA. Protein-bound uremic toxins: new insight from clinical studies. Toxins (Basel) 2011;3:911-9.
19. Bianchi-Salvadori B, Vesely R, Ferrari A, Canzi E, Casiraghi C, Brighenti F. Behaviour of the pharmaceutical probiotic preparation VSL#3 in human ileostomy effluent containing its own natural elements. New Microbiol 2001;24:23-33.
20. Brigidi P, Swennen E, Vitali B, Rossi M, Matteuzzi D. PCR detection of Bifidobacterium strains and Streptococcus thermophilus in feces of human subjects after oral bacteriotherapy and yogurt consumption. Int J Food Microbiol 2003;81:203-9.
21. Ranganathan N, Friedman EA, Tam P, Rao V, Ranganathan P, Dheer R. Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada. Curr Med Res Opin 2009;25:1919-30.